Bright Minds Biosciences (DRUG) Accounts Payables (2020 - 2026)

Bright Minds Biosciences has reported Accounts Payables for 7 years, with the latest figure at $2.7 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 3438.07% year-over-year to $2.7 million; the trailing twelve-month figure through Mar 2026 stood at $2.7 million (up 3438.07% YoY), and the FY2025 full-year result was $1.6 million, up 447.45% from the prior year.
• Accounts Payables for Q1 2026 stood at $2.7 million, up from $1.1 million in the prior quarter.
• The five-year high for Accounts Payables was $2.7 million in Q1 2026, with the low at -$697200.2 in Q4 2022.
• Historically, Accounts Payables has averaged $465944.8 across 5 years, with a median of $288112.7 in 2022.
• Annual changes were most pronounced in 2022 — Accounts Payables sank 689.9% — and 2026, when it jumped 3438.07%.
• Bright Minds Biosciences' Accounts Payables stood at -$697200.2 in 2022, then surged by 162.4% to $435058.0 in 2023, then slumped by 109.95% to -$43267.4 in 2024, then soared by 2576.73% to $1.1 million in 2025, then surged by 155.22% to $2.7 million in 2026.
• The last three Accounts Payables figures came in at $2.7 million (Q1 2026), $1.1 million (Q4 2025), and $1.6 million (Q3 2025), per Business Quant data.